G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma
- Sponsor
- Navy General Hospital, Beijing
- Study ID
- NCT07184788
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Aggressive B-Cell Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 14 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy — DRUGPatients were treated by Glofitama(Cycle 1: D8, 2.5mg, D15, 10mg; followed by the target dose of 30mg on D1 of Cycle 2-12), Polatuzumab Vedotin(1.8mg/kg iv qd d1), Gemcitabine (1000 mg/m2 iv qd d2), Oxaliplatin (100 mg/m2 iv qd d2) as induction therapy.
Study Details
The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-GemOx as induction therapy in patients with Refractory/Relapsed Aggressive B-Cell Lymphoma.
Key Dates
- Start date
- Oct 1, 2025
- Status verified
- Sep 2025
- Primary completion
- Oct 1, 2030
- Completion
- Oct 1, 2031
Study Design
- Enrollment
- 80 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Induction TherapyPatients were treated by G-Pola-GemOx as Induction Therapy
Primary Outcome Measure
Overall Response Rate (ORR) [ Time Frame: 1 year ]
Central Contacts
- Liren Qian+861066947194
- Liren Qian